<DOC>
	<DOCNO>NCT00276601</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell . PURPOSE : This phase II trial study well give combination chemotherapy work treat patient acute promyelocytic leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Acute Promyelocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine , preliminarily , safety incorporate arsenic trioxide ( ATO ) cytarabine daunorubicin hydrochloride-based consolidation therapy follow tretinoin maintenance therapy patient receive induction tretinoin daunorubicin hydrochloride acute promyelocytic leukemia ( APL ) induce remission tretinoin daunorubicin hydrochloride . - Determine , preliminarily , efficacy strategy induce maintain molecular remission patient treat regimen . OUTLINE : This pilot , multicenter study . - Induction therapy : Patients receive oral tretinoin twice daily day 1-60 daunorubicin hydrochloride IV day 4 , 6 , 8 . Patients evaluated day 60-67 proceed consolidation therapy . - Consolidation therapy : Patients receive cytarabine IV continuously day 1-3 , daunorubicin hydrochloride IV day 1-3 , arsenic trioxide IV 1-2 hour daily , 5 day week , begin day 8 continue 6 week . Patients clinical and/or cytogenic , molecular , remission receive additional arsenic trioxide daily , 5 day week , 30 dos ( 6 week ) . Patients achieve clinical molecular remission completion 6 12 week arsenic trioxide proceed maintenance therapy . - Maintenance therapy : Patients receive oral tretinoin daily day 1-15 . Treatment repeat every 3 month 8 course ( 2 year ) . After completion study treatment , patient follow periodically 5 year . PROJECTED ACCRUAL : A total 50 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis acute promyelocytic leukemia ( APL ) morphologic flow cytometric documentation ( high orthogonal light scatter , lack HLADR expression ) Patients classical APL well microgranular variant ( M3V ) eligible In case diagnosis unclear , consultation hematopathologist require enrol patient study Patients find cytogenetic abnormality produce PMLRARÎ± gene rearrangement remove study include data analysis PATIENT CHARACTERISTICS : Patients exclude performance status comorbid disease Premenopausal female patient must negative pregnancy test PRIOR CONCURRENT THERAPY : No prior chemotherapy APL except hydroxyurea</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>untreated childhood acute myeloid leukemia myeloid malignancy</keyword>
	<keyword>adult acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>childhood acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
</DOC>